Envas Injection contains Enalaprilat 1.25 mg, the active metabolite of enalapril, classified as an angiotensin-converting enzyme (ACE) inhibitor. It is indicated for the treatment of hypertension and acute decompensated heart failure, particularly in patients unable to take oral medications. Enalaprilat exerts its therapeutic effect by inhibiting the ACE enzyme, thereby reducing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This results in vasodilation, decreased peripheral vascular resistance, and lowered blood pressure, ultimately improving cardiac output and reducing the workload on the heart. Envas Injection is administered intravenously, allowing rapid onset of action, making it suitable for acute settings. The dosage should be individualized based on clinical response and patient tolerance, with careful monitoring of blood pressure, renal function, and serum electrolytes during therapy. Caution is advised in patients with renal impairment, hypotension, or a history of angioedema related to ACE inhibitors. Common adverse effects may include hypotension, dizziness, and renal function alterations. Envas Injection should be used under strict medical supervision, ensuring appropriate patient selection and dosage adjustment to optimize therapeutic outcomes while minimizing risks.